Matches in SemOpenAlex for { <https://semopenalex.org/work/W2427831715> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2427831715 endingPage "9" @default.
- W2427831715 startingPage "1803" @default.
- W2427831715 abstract "The combination of cisplatin and vinorelbine has been shown to be effective in patients with advanced non-small cell lung cancer (NSCLC). Based on these data, we planned to treat patients with stage IIIB NSCLC without malignant pleural effusion and/or metastatic supraclavicular lymph nodes, in order to study the potential effectiveness of this association as neoadjuvant treatment.Thirty patients entered into the study and were treated preoperatively with cisplatin 120 mg/m2 given on day 1 and vinorelbine 30 mg/m2 given on days 1 and 8, recycled every 3 weeks for a maximum of 3 cycles. The main characteristics of patients were: male/female 23/7, median age 61 years, performance status 0/1/2, 8/17/5. Only patients who achieved an objective response underwent surgery.A total of 82 (91.1%) cycles were administered with moderate toxicity: WHO grade (G) 2 and 3 neutropenia occurred in 20 (66.6%) patients, G 3 anaemia occurred in 4 (13.3%), G 3 nausea/vomiting in 20 (66.6%) and G 1-2 renal toxicity in 2 (6.6%). Eighteen (60%; exact 95% confidence limits, 40.6% to 77.3%) patients achieved a partial response and 14 (46.6%) underwent surgery. Complete resection (R0) was achieved in 11 (36.6% of all patients) and pathological complete resection in 5 (16.6%). No postoperative pulmonary complications were reported. The median survival for all patients was 25.5 (exact 95% confidence limits, 13 to 39) months. The median progression-free survival in responsive patients was 27 (exact 95% confidence limits, 13 to 33) months.The combination of cisplatin and vinorelbine is effective and safe as a neoadjuvant therapy in stage IIIB NSCLC, showing a high response rate (60%) and amenability to surgery." @default.
- W2427831715 created "2016-06-24" @default.
- W2427831715 creator A5012782858 @default.
- W2427831715 creator A5020137382 @default.
- W2427831715 creator A5046785006 @default.
- W2427831715 creator A5058578920 @default.
- W2427831715 creator A5061005482 @default.
- W2427831715 creator A5063115082 @default.
- W2427831715 date "2003-06-25" @default.
- W2427831715 modified "2023-09-23" @default.
- W2427831715 title "Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study." @default.
- W2427831715 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12820462" @default.
- W2427831715 hasPublicationYear "2003" @default.
- W2427831715 type Work @default.
- W2427831715 sameAs 2427831715 @default.
- W2427831715 citedByCount "4" @default.
- W2427831715 countsByYear W24278317152018 @default.
- W2427831715 crossrefType "journal-article" @default.
- W2427831715 hasAuthorship W2427831715A5012782858 @default.
- W2427831715 hasAuthorship W2427831715A5020137382 @default.
- W2427831715 hasAuthorship W2427831715A5046785006 @default.
- W2427831715 hasAuthorship W2427831715A5058578920 @default.
- W2427831715 hasAuthorship W2427831715A5061005482 @default.
- W2427831715 hasAuthorship W2427831715A5063115082 @default.
- W2427831715 hasConcept C126322002 @default.
- W2427831715 hasConcept C141071460 @default.
- W2427831715 hasConcept C2776232967 @default.
- W2427831715 hasConcept C2776256026 @default.
- W2427831715 hasConcept C2776694085 @default.
- W2427831715 hasConcept C2776907518 @default.
- W2427831715 hasConcept C2777063308 @default.
- W2427831715 hasConcept C2778239845 @default.
- W2427831715 hasConcept C2779634585 @default.
- W2427831715 hasConcept C2780350996 @default.
- W2427831715 hasConcept C2780580376 @default.
- W2427831715 hasConcept C31760486 @default.
- W2427831715 hasConcept C71924100 @default.
- W2427831715 hasConcept C90924648 @default.
- W2427831715 hasConceptScore W2427831715C126322002 @default.
- W2427831715 hasConceptScore W2427831715C141071460 @default.
- W2427831715 hasConceptScore W2427831715C2776232967 @default.
- W2427831715 hasConceptScore W2427831715C2776256026 @default.
- W2427831715 hasConceptScore W2427831715C2776694085 @default.
- W2427831715 hasConceptScore W2427831715C2776907518 @default.
- W2427831715 hasConceptScore W2427831715C2777063308 @default.
- W2427831715 hasConceptScore W2427831715C2778239845 @default.
- W2427831715 hasConceptScore W2427831715C2779634585 @default.
- W2427831715 hasConceptScore W2427831715C2780350996 @default.
- W2427831715 hasConceptScore W2427831715C2780580376 @default.
- W2427831715 hasConceptScore W2427831715C31760486 @default.
- W2427831715 hasConceptScore W2427831715C71924100 @default.
- W2427831715 hasConceptScore W2427831715C90924648 @default.
- W2427831715 hasIssue "2C" @default.
- W2427831715 hasLocation W24278317151 @default.
- W2427831715 hasOpenAccess W2427831715 @default.
- W2427831715 hasPrimaryLocation W24278317151 @default.
- W2427831715 hasRelatedWork W1562964855 @default.
- W2427831715 hasRelatedWork W2090927803 @default.
- W2427831715 hasRelatedWork W2144499377 @default.
- W2427831715 hasRelatedWork W2348253150 @default.
- W2427831715 hasRelatedWork W2377654551 @default.
- W2427831715 hasRelatedWork W2384154403 @default.
- W2427831715 hasRelatedWork W2411701263 @default.
- W2427831715 hasRelatedWork W2427831715 @default.
- W2427831715 hasRelatedWork W2468511872 @default.
- W2427831715 hasRelatedWork W3138941791 @default.
- W2427831715 hasVolume "23" @default.
- W2427831715 isParatext "false" @default.
- W2427831715 isRetracted "false" @default.
- W2427831715 magId "2427831715" @default.
- W2427831715 workType "article" @default.